RNA (New York, N.Y.)

Keyphrases

Publications

volume 29, number 4, 2023

Krystal C Johnson, David R Corey
RNAi in cell nuclei: potential for a new layer of biological regulation and a new strategy for therapeutic discovery. RNA (New York, N.Y.) 29 (4) (2023)
Juan F Diaz Quiroz, Louise D Siskel, Joshua J C Rosenthal
Site-directed A → I RNA editing as a therapeutic tool: moving beyond genetic mutations. RNA (New York, N.Y.) 29 (4) (2023)
Sai Pallavi Pradeep, Shipra Malik, Frank J Slack, Raman Bahal
Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Jonathan Hall
Future directions for medicinal chemistry in the field of oligonucleotide therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Annemieke Aarstma-Rus, Willeke M C van Roon-Mom, Marlen Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA (New York, N.Y.) 29 (4) (2023)
Sai Pallavi Pradeep, Shipra Malik, Frank J Slack, Raman Bahal
Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Greta Bagnolini, TinTin B Luu, Amanda E Hargrove
Recognizing the power of machine learning and other computational methods to accelerate progress in small molecule targeting of RNA. RNA (New York, N.Y.) 29 (4) (2023)
Krystal C Johnson, David R Corey
RNAi in cell nuclei: potential for a new layer of biological regulation and a new strategy for therapeutic discovery. RNA (New York, N.Y.) 29 (4) (2023)
Sai Pallavi Pradeep, Shipra Malik, Frank J Slack, Raman Bahal
Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Elliott B Nickbarg, Kerrie B Spencer, Jonathan D Mortison, Jeannie T Lee
Targeting RNA with small molecules: lessons learned from Xist RNA. RNA (New York, N.Y.) 29 (4) (2023)
Haixiang Yu, James Frederiksen, Bruce A Sullenger
Applications and future of aptamers that achieve rapid-onset anticoagulation. RNA (New York, N.Y.) 29 (4) (2023)
Krystal C Johnson, David R Corey
RNAi in cell nuclei: potential for a new layer of biological regulation and a new strategy for therapeutic discovery. RNA (New York, N.Y.) 29 (4) (2023)
Elliott B Nickbarg, Kerrie B Spencer, Jonathan D Mortison, Jeannie T Lee
Targeting RNA with small molecules: lessons learned from Xist RNA. RNA (New York, N.Y.) 29 (4) (2023)
Steven F Dowdy
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA (New York, N.Y.) 29 (4) (2023)
Haixiang Yu, James Frederiksen, Bruce A Sullenger
Applications and future of aptamers that achieve rapid-onset anticoagulation. RNA (New York, N.Y.) 29 (4) (2023)
Ariel Bashari, Zahava Siegfried, Rotem Karni
Targeting splicing factors for cancer therapy. RNA (New York, N.Y.) 29 (4) (2023)
Jonathan Hall
Future directions for medicinal chemistry in the field of oligonucleotide therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Steven F Dowdy
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA (New York, N.Y.) 29 (4) (2023)
Greta Bagnolini, TinTin B Luu, Amanda E Hargrove
Recognizing the power of machine learning and other computational methods to accelerate progress in small molecule targeting of RNA. RNA (New York, N.Y.) 29 (4) (2023)
Martin Egli, Mark K Schlegel, Muthiah Manoharan
Acyclic ( S )-glycol nucleic acid ( S -GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency. RNA (New York, N.Y.) 29 (4) (2023)
Steven F Dowdy
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA (New York, N.Y.) 29 (4) (2023)
Haixiang Yu, James Frederiksen, Bruce A Sullenger
Applications and future of aptamers that achieve rapid-onset anticoagulation. RNA (New York, N.Y.) 29 (4) (2023)
Juan F Diaz Quiroz, Louise D Siskel, Joshua J C Rosenthal
Site-directed A → I RNA editing as a therapeutic tool: moving beyond genetic mutations. RNA (New York, N.Y.) 29 (4) (2023)
Kathryn H Morelli, Aaron A Smargon, Gene W Yeo
Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders. RNA (New York, N.Y.) 29 (4) (2023)
Greta Bagnolini, TinTin B Luu, Amanda E Hargrove
Recognizing the power of machine learning and other computational methods to accelerate progress in small molecule targeting of RNA. RNA (New York, N.Y.) 29 (4) (2023)
Ariel Bashari, Zahava Siegfried, Rotem Karni
Targeting splicing factors for cancer therapy. RNA (New York, N.Y.) 29 (4) (2023)
Steven F Dowdy
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA (New York, N.Y.) 29 (4) (2023)
Martin Egli, Mark K Schlegel, Muthiah Manoharan
Acyclic ( S )-glycol nucleic acid ( S -GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency. RNA (New York, N.Y.) 29 (4) (2023)
Kathryn H Morelli, Aaron A Smargon, Gene W Yeo
Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders. RNA (New York, N.Y.) 29 (4) (2023)
Ariel Bashari, Zahava Siegfried, Rotem Karni
Targeting splicing factors for cancer therapy. RNA (New York, N.Y.) 29 (4) (2023)
Juan F Diaz Quiroz, Louise D Siskel, Joshua J C Rosenthal
Site-directed A → I RNA editing as a therapeutic tool: moving beyond genetic mutations. RNA (New York, N.Y.) 29 (4) (2023)
Annemieke Aarstma-Rus, Willeke M C van Roon-Mom, Marlen Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA (New York, N.Y.) 29 (4) (2023)
Greta Bagnolini, TinTin B Luu, Amanda E Hargrove
Recognizing the power of machine learning and other computational methods to accelerate progress in small molecule targeting of RNA. RNA (New York, N.Y.) 29 (4) (2023)
Martin Egli, Mark K Schlegel, Muthiah Manoharan
Acyclic ( S )-glycol nucleic acid ( S -GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency. RNA (New York, N.Y.) 29 (4) (2023)
Haixiang Yu, James Frederiksen, Bruce A Sullenger
Applications and future of aptamers that achieve rapid-onset anticoagulation. RNA (New York, N.Y.) 29 (4) (2023)
Elliott B Nickbarg, Kerrie B Spencer, Jonathan D Mortison, Jeannie T Lee
Targeting RNA with small molecules: lessons learned from Xist RNA. RNA (New York, N.Y.) 29 (4) (2023)
Martin Egli, Mark K Schlegel, Muthiah Manoharan
Acyclic ( S )-glycol nucleic acid ( S -GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency. RNA (New York, N.Y.) 29 (4) (2023)
Kathryn H Morelli, Aaron A Smargon, Gene W Yeo
Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders. RNA (New York, N.Y.) 29 (4) (2023)
Annemieke Aarstma-Rus, Willeke M C van Roon-Mom, Marlen Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA (New York, N.Y.) 29 (4) (2023)
Kathryn H Morelli, Aaron A Smargon, Gene W Yeo
Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders. RNA (New York, N.Y.) 29 (4) (2023)
Jonathan Hall
Future directions for medicinal chemistry in the field of oligonucleotide therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Elliott B Nickbarg, Kerrie B Spencer, Jonathan D Mortison, Jeannie T Lee
Targeting RNA with small molecules: lessons learned from Xist RNA. RNA (New York, N.Y.) 29 (4) (2023)
Sai Pallavi Pradeep, Shipra Malik, Frank J Slack, Raman Bahal
Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Krystal C Johnson, David R Corey
RNAi in cell nuclei: potential for a new layer of biological regulation and a new strategy for therapeutic discovery. RNA (New York, N.Y.) 29 (4) (2023)
Juan F Diaz Quiroz, Louise D Siskel, Joshua J C Rosenthal
Site-directed A → I RNA editing as a therapeutic tool: moving beyond genetic mutations. RNA (New York, N.Y.) 29 (4) (2023)
Michelle L Hastings, Adrian R Krainer
RNA therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Annemieke Aarstma-Rus, Willeke M C van Roon-Mom, Marlen Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA (New York, N.Y.) 29 (4) (2023)
Ariel Bashari, Zahava Siegfried, Rotem Karni
Targeting splicing factors for cancer therapy. RNA (New York, N.Y.) 29 (4) (2023)
Jonathan Hall
Future directions for medicinal chemistry in the field of oligonucleotide therapeutics. RNA (New York, N.Y.) 29 (4) (2023)
Juan F Diaz Quiroz, Louise D Siskel, Joshua J C Rosenthal
Site-directed A → I RNA editing as a therapeutic tool: moving beyond genetic mutations. RNA (New York, N.Y.) 29 (4) (2023)